Skip Ribbon Commands
Skip to main content

 

The investigator-initiated MASTER DAPT study demonstrates that one month of DAPT was non-inferior to treatment continuation for at least 2 additional months for the occurrence of net and major adverse clinical events, and reduced major or clinically relevant non-major bleeding.

MASTER DAPT, the largest multi-center randomized controlled study on the use of short duration of dual antiplatelet therapy (DAPT) in high bleeding risk patients following stenting procedures with Ultimaster™/Ultimaster™TanseiTM drug-eluting bioresorbable polymer stents (DES). 

A total cohort of 4.579 patients have been randomized into this ambitious study.

The UltimasterTM Clinical Program included one of the largest, prospective worldwide registries, the e- ULTIMASTER™ with 37,198 patients. The Ultimaster™ Clinical Program² demonstrates the safe and effective use of the Ultimaster stent in different patient cohorts, representative of daily PCI practice. 

Total Population
  • 37,178 patients enrolled in the e-ULTIMASTER™ registry, one of the largest, prospective worldwide registries.
  • e-ULTIMASTER™– a truly all comer's DES clinical registry.
Complex PCI
  • e-ULTIMASTER™ all-comer registry enrolled more than 10,000 patients meeting complex PCI criteria.
  • Complex PCI was defined as:
    - Multivessel PCI > 3 stents implanted > 3 lesions treated.
    - Bifurcation PCI with > 2 stents, total stent length > 60mm and chronic total occlusion.
Bifurcation
  • 4,395 patients with bifurcation lesions treated with Ultimaster™ DES showed excellent clinical outcomes with TLF of 5.1% at 1 year. 
  • Use of the proximal optimization technique (POT) was associated with a better clinical outcome with respect to TLF and TVF at 1 year. This was due to a strong impact on the risk of TV-MI, stent thrombosis and revascularisation.
Multivessel Disease
  • The revascularization strategy (complete versus incomplete revascularization) in multivessel disease patients treated with Ultimaster™ DES was assessed at 1-year follow-up.
  • Complete revascularization was associated with better relief from angina, lower mortality, less target vessel failure (TVF), and lower patient oriented composite endpoint (POCE).
  • Ultimaster™ DES demonstrated excellent results in this complex population.

Largest study to date on 1-year outcomes post-PCI, in an unselected, real-world cohort of patients enrolled in the e-ULTIMASTER registry.

The aim of the study was to understand the prevalence, clinical characteristics, and 1-year outcomes of patients with complex lesions in an unselected cohort of over 35,000 patients who underwent PCI with the Ultimaster™ DES system.”

Download clinical summary

Power of n

What the evidence says

Discover our clinical evidence and case studies concerning this topic.

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
 
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public


For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.